Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Stefania Angelicola
Observed names:
Angelicola, Stefania,
S. Angelicola
Institutions:
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
Regione Emilia-Romagna
Observed institutions:
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
Regione Emilia-Romagna,
University of Bologna
ORCID:
0000-0001-9495-5147
Observed ORCID:
0000-0001-9495-5147
OpenAlex ID:
A5007579771
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy
2023
·
Francesca Ruzzi
, Maria Sofia Semprini
, et al.
·
International Journal of Molecular Sciences
·
53
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?
2024
·
Francesca Ruzzi
, Chiara Cappello
, et al.
·
Cell Communication and Signaling
·
49
PDF
IFN-γ and CD38 in Hyperprogressive Cancer Development
2021
·
Stefania Angelicola
, Francesca Ruzzi
, et al.
·
Cancers
·
33
PDF
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD)
2025
·
Stefania Angelicola
, Francesca Giunchi
, et al.
·
Journal of Translational Medicine
·
18
PDF
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC
2022
·
Francesca Ruzzi
, Stefania Angelicola
, et al.
·
Translational Lung Cancer Research
·
13
PDF
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma
2025
·
Laura Scalambra
, Francesca Ruzzi
, et al.
·
Journal of Translational Medicine
·
12
PDF
Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine
2022
·
Francesca Ruzzi
, Arianna Palladini
, et al.
·
Biomedicines
·
11
PDF
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations
2024
·
Alessandro Di Federico
, Stefania Angelicola
, et al.
·
JCO Precision Oncology
·
9
Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC
2026
·
A. Cavazzoni
, M. Pagano Mariano
, et al.
·
Lung Cancer
·
3
Alternatives for fetal bovine serum (FBS) and sustainability of milk derivatives in cell culture
2026
·
Olga Maria Pittino
, Maria Sofia Semprini
, et al.
·
Biological Research
·
2
Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay
2024
·
Francesca Ruzzi
, Maria Sofia Semprini
, et al.
·
Methods in cell biology
·
2
Abstract 687: Preclinical activity of ES2B-C001, a human candidate HER-2 virus-like particle (VLP) vaccine, against mammary carcinoma onset and metastasis
2023
·
Francesca Ruzzi
, Arianna Palladini
, et al.
·
Cancer Research
·
1
Coexistence of Osimertinib-Resistant and Osimertinib-Sensitive cell states in an EGFR-Mutant NSCLC model derived at osimertinib resistance
2026
·
Ilaria C. Chillico
, Mariateresa Frascino
, et al.
·
Lung Cancer
PDF
Beyond immune surveillance: IFN-γ and PD-L1 as shapers of tumor plasticity in Non-Small Cell Lung Cancer (NSCLC)
2026
·
Stefania Angelicola
, Mariateresa Frascino
, et al.
·
Frontiers in Immunology
PDF
HER-2 therapeutic vaccine is not hampered by concurrent HER-2 monoclonal antibody
2026
·
Maria Sofia Semprini
, Chiara Cappello
, et al.
·
npj Vaccines
PDF
Requalified bovine milk as a sustainable supplement for cell cultures
2026
·
Maria Sofia Semprini
, Olga Maria Pittino
, et al.
·
Discover Food
HER-2 therapeutic vaccine is not hampered by concurrent HER-2 monoclonal antibody
2026
·
Semprini, Maria Sofia
, Cappello, Chiara
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
Erratum: Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations
2026
·
Alessandro Di Federico
, Stefania Angelicola
, et al.
·
JCO Precision Oncology
Phenotypic Changes in NSCLC Organoids Captured via Micro-CT Radiomics following IFN-γ Exposure
2026
·
Ilaria Chillico
, Leonardo Brizzi
, et al.
·
SSRN Electronic Journal
Development of cellular models expressing cynomolgus (Macaca fascicularis) HER2 for the functional evaluation of cross-reactive anti-human HER2 response
2025
·
Chiara Cappello
, Francesca Ruzzi
, et al.
·
Frontiers in Pharmacology
PDF
P1.11.54 Lack of Durable Response to ICI Therapy in Advanced NSCLC: The Role of Circulating Lazy T Cells
2025
·
A. Palladini
, P.L.S. Michel
, et al.
·
Journal of Thoracic Oncology
355P: Effect of immunotherapy on the peripheral immunoscore of patients affected by non-small cell lung cancer long responders or fast progressors
2025
·
N.L. Alessio
, P. Michel
, et al.
·
Journal of Thoracic Oncology
PDF
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), through an innovative virus-like particles (VLP)-based vaccine, enhance the antitumoral activity of a HER-2-VLP vaccine in a preclinical model of HER-2 positive breast cancer
2024
·
F. Ruzzi
, L. Scalambra
, et al.
·
European Journal of Cancer
PDF
Show more works
View as search
Works count:
24
Citation count:
206
H-index:
8
I10-index:
7
Year
Topic
Type